Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Cash & Equivalents (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Cash & Equivalents for 6 consecutive years, with $78.7 million as the latest value for Q3 2024.

  • On a quarterly basis, Cash & Equivalents fell 5.2% to $78.7 million in Q3 2024 year-over-year; TTM through Sep 2024 was $78.7 million, a 5.2% decrease, with the full-year FY2023 number at $76.7 million, down 29.6% from a year prior.
  • Cash & Equivalents was $78.7 million for Q3 2024 at Actinium Pharmaceuticals, down from $86.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $116.3 million in Q2 2022 to a low of $72.0 million in Q1 2022.
  • A 4-year average of $87.9 million and a median of $83.0 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 41.26% in 2022, then decreased 29.6% in 2023.
  • Actinium Pharmaceuticals' Cash & Equivalents stood at $77.8 million in 2021, then skyrocketed by 39.93% to $108.9 million in 2022, then fell by 29.6% to $76.7 million in 2023, then grew by 2.59% to $78.7 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Cash & Equivalents are $78.7 million (Q3 2024), $86.0 million (Q2 2024), and $84.1 million (Q1 2024).